Multiple sclerosis following SARS-CoV-2 infection

•The first case of multiple sclerosis (MS) shortly after COVID-19 is presented.•Viral infections strongly relate to MS onset and its relapses.•SARS-CoV-2 can play a role in the triggering of demyelinating diseases.•Systemic immune response against SARS-CoV-2 could reach CNS leading to demyelination....

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Multiple sclerosis and related disorders Ročník 45; s. 102377
Hlavní autoři: Palao, M., Fernández-Díaz, E., Gracia-Gil, J., Romero-Sánchez, C.M., Díaz-Maroto, I., Segura, T.
Médium: Journal Article
Jazyk:angličtina
Vydáno: Netherlands Elsevier B.V 01.10.2020
Témata:
Adult
Betacoronavirus
Coronavirus Infections - complications
COVID-19
Demyelinating disease
Female
Humans
MHV-59
Multiple Sclerosis - epidemiology
Multiple Sclerosis - pathology
Neurology
Optic neuritis
Original
Pandemics
Pneumonia, Viral - complications
SARS-CoV-2
COVID-19
Demyelinating disease
SARS-CoV-2
MHV-59
Optic neuritis
ISSN:2211-0348, 2211-0356, 2211-0356
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract •The first case of multiple sclerosis (MS) shortly after COVID-19 is presented.•Viral infections strongly relate to MS onset and its relapses.•SARS-CoV-2 can play a role in the triggering of demyelinating diseases.•Systemic immune response against SARS-CoV-2 could reach CNS leading to demyelination. SARS-CoV-2 infection can produce neurological features. The most common are headache, anosmia and dysgeusia but patients may also develop other central nervous system (CNS) injuries. We present a patient affected by Covid-19 who initially consulted for decreased visual acuity. The MRI showed inflammation in the right optic nerve and demyelinating lesions in the CNS. We speculate that an immune mechanism induced by SARS-CoV-2, which can activate lymphocytes and an inflammatory response, plays a role in the clinical onset of the disease. This pathogen may be associated with either the triggering or the exacerbation of inflammatory/demyelinating disease.
AbstractList •The first case of multiple sclerosis (MS) shortly after COVID-19 is presented.•Viral infections strongly relate to MS onset and its relapses.•SARS-CoV-2 can play a role in the triggering of demyelinating diseases.•Systemic immune response against SARS-CoV-2 could reach CNS leading to demyelination. SARS-CoV-2 infection can produce neurological features. The most common are headache, anosmia and dysgeusia but patients may also develop other central nervous system (CNS) injuries. We present a patient affected by Covid-19 who initially consulted for decreased visual acuity. The MRI showed inflammation in the right optic nerve and demyelinating lesions in the CNS. We speculate that an immune mechanism induced by SARS-CoV-2, which can activate lymphocytes and an inflammatory response, plays a role in the clinical onset of the disease. This pathogen may be associated with either the triggering or the exacerbation of inflammatory/demyelinating disease.
• The first case of multiple sclerosis (MS) shortly after COVID-19 is presented. • Viral infections strongly relate to MS onset and its relapses. • SARS-CoV-2 can play a role in the triggering of demyelinating diseases. • Systemic immune response against SARS-CoV-2 could reach CNS leading to demyelination. SARS-CoV-2 infection can produce neurological features. The most common are headache, anosmia and dysgeusia but patients may also develop other central nervous system (CNS) injuries. We present a patient affected by Covid-19 who initially consulted for decreased visual acuity. The MRI showed inflammation in the right optic nerve and demyelinating lesions in the CNS. We speculate that an immune mechanism induced by SARS-CoV-2, which can activate lymphocytes and an inflammatory response, plays a role in the clinical onset of the disease. This pathogen may be associated with either the triggering or the exacerbation of inflammatory/demyelinating disease.
SARS-CoV-2 infection can produce neurological features. The most common are headache, anosmia and dysgeusia but patients may also develop other central nervous system (CNS) injuries. We present a patient affected by Covid-19 who initially consulted for decreased visual acuity. The MRI showed inflammation in the right optic nerve and demyelinating lesions in the CNS. We speculate that an immune mechanism induced by SARS-CoV-2, which can activate lymphocytes and an inflammatory response, plays a role in the clinical onset of the disease. This pathogen may be associated with either the triggering or the exacerbation of inflammatory/demyelinating disease.SARS-CoV-2 infection can produce neurological features. The most common are headache, anosmia and dysgeusia but patients may also develop other central nervous system (CNS) injuries. We present a patient affected by Covid-19 who initially consulted for decreased visual acuity. The MRI showed inflammation in the right optic nerve and demyelinating lesions in the CNS. We speculate that an immune mechanism induced by SARS-CoV-2, which can activate lymphocytes and an inflammatory response, plays a role in the clinical onset of the disease. This pathogen may be associated with either the triggering or the exacerbation of inflammatory/demyelinating disease.
SARS-CoV-2 infection can produce neurological features. The most common are headache, anosmia and dysgeusia but patients may also develop other central nervous system (CNS) injuries. We present a patient affected by Covid-19 who initially consulted for decreased visual acuity. The MRI showed inflammation in the right optic nerve and demyelinating lesions in the CNS. We speculate that an immune mechanism induced by SARS-CoV-2, which can activate lymphocytes and an inflammatory response, plays a role in the clinical onset of the disease. This pathogen may be associated with either the triggering or the exacerbation of inflammatory/demyelinating disease.
Highlights•The first case of multiple sclerosis (MS) shortly after COVID-19 is presented. •Viral infections strongly relate to MS onset and its relapses. •SARS-CoV-2 can play a role in the triggering of demyelinating diseases. •Systemic immune response against SARS-CoV-2 could reach CNS leading to demyelination.
ArticleNumber 102377
Author Segura, T.
Palao, M.
Gracia-Gil, J.
Romero-Sánchez, C.M.
Fernández-Díaz, E.
Díaz-Maroto, I.
Author_xml – sequence: 1
  givenname: M.
  orcidid: 0000-0002-3229-0060
  surname: Palao
  fullname: Palao, M.
  email: mariapalaorico@gmail.com
– sequence: 2
  givenname: E.
  orcidid: 0000-0003-0936-5615
  surname: Fernández-Díaz
  fullname: Fernández-Díaz, E.
– sequence: 3
  givenname: J.
  surname: Gracia-Gil
  fullname: Gracia-Gil, J.
– sequence: 4
  givenname: C.M.
  surname: Romero-Sánchez
  fullname: Romero-Sánchez, C.M.
– sequence: 5
  givenname: I.
  surname: Díaz-Maroto
  fullname: Díaz-Maroto, I.
– sequence: 6
  givenname: T.
  orcidid: 0000-0003-3625-0987
  surname: Segura
  fullname: Segura, T.
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32698095$$D View this record in MEDLINE/PubMed
BookMark eNqFUltrFDEUDlKxtfYXCLKPvsya62QGsVAWb1ARXPX1kMmcqVmzyZrMVPrvzbht0YI2Lwkn3wW-7zwmByEGJOQpo0tGWf1is9xmk_olp3yecKH1A3LEOWMVFao-uH3L5pCc5Lyh5dSKyZo9IoeC121DW3VE2IfJj27ncZGtxxSzy4sheh9_unCxWJ99Wler-LXiCxcGtKOL4Ql5OBif8eT6PiZf3rz-vHpXnX98-351dl5ZJbWuWkqZFNQo2jDNbasH0fSspm2rlcJOK61Q6sFKyzVyK7gaCqhXsqv7ruulOCane93d1G2xtxjGZDzsktuadAXROPj7J7hvcBEvQQtJqdJF4Pm1QIo_JswjbF226L0JGKcMXPJaCdXUTYE--9Pr1uQmpwJo9wBbIsoJB7BuNHMcxdp5YBTmWmADv2uBuRbY11K44g73Rv7_rFd7FpaMLx0myNZhsNi7VIqAPrp7-Kd3-Na74Kzx3_EK8yZOKZT6gEHmQGE9r8u8LZwKKhVnReDlvwXutf8F5r_N1g
CitedBy_id crossref_primary_10_3389_fneur_2021_711026
crossref_primary_10_1016_j_neurad_2021_07_004
crossref_primary_10_3390_ijms22168965
crossref_primary_10_1515_revneuro_2021_0148
crossref_primary_10_3390_neurolint13040066
crossref_primary_10_1007_s00415_022_11237_1
crossref_primary_10_7759_cureus_17297
crossref_primary_10_1016_j_jns_2021_117316
crossref_primary_10_1016_j_jneuroim_2021_577785
crossref_primary_10_1007_s12035_021_02450_6
crossref_primary_10_1093_brain_awab302
crossref_primary_10_1016_j_mehy_2020_110345
crossref_primary_10_4103_tjo_TJO_D_23_00124
crossref_primary_10_1007_s10465_023_09387_4
crossref_primary_10_1007_s12640_021_00389_z
crossref_primary_10_3390_ijms22041804
crossref_primary_10_1016_j_jneuroim_2022_577939
crossref_primary_10_1109_JSEN_2021_3076102
crossref_primary_10_1159_000521891
crossref_primary_10_1186_s41983_021_00322_3
crossref_primary_10_1016_j_jaut_2023_103070
crossref_primary_10_1007_s10522_025_10252_9
crossref_primary_10_1080_14647273_2023_2262757
crossref_primary_10_1007_s42399_020_00504_9
crossref_primary_10_1186_s12883_024_03956_x
crossref_primary_10_1590_1806_9282_20231061
crossref_primary_10_1002_eji_202250230
crossref_primary_10_1016_j_clnesp_2021_06_011
crossref_primary_10_3390_ijms22083859
crossref_primary_10_1016_j_clineuro_2021_106760
crossref_primary_10_1055_s_0043_1767713
crossref_primary_10_1097_WNO_0000000000002234
crossref_primary_10_1055_s_0043_1767715
crossref_primary_10_1097_YCO_0000000000000688
crossref_primary_10_1016_j_jim_2023_113556
crossref_primary_10_1080_1744666X_2022_2064845
crossref_primary_10_3389_fnagi_2021_662786
crossref_primary_10_3389_fneur_2022_970383
crossref_primary_10_1016_j_sedeng_2024_05_005
crossref_primary_10_1177_26331055241265668
crossref_primary_10_3390_v12080880
crossref_primary_10_1016_j_msard_2021_102863
crossref_primary_10_1515_revneuro_2020_0154
crossref_primary_10_3390_app122211531
crossref_primary_10_1007_s12035_021_02383_0
crossref_primary_10_12688_f1000research_28393_1
crossref_primary_10_3389_fimmu_2022_871276
crossref_primary_10_1016_j_autrev_2021_102803
crossref_primary_10_7759_cureus_16857
crossref_primary_10_3389_fcimb_2024_1407261
crossref_primary_10_1016_j_autrev_2021_102888
crossref_primary_10_1016_j_clineuro_2024_108160
crossref_primary_10_1016_j_yaoo_2021_04_017
crossref_primary_10_3389_fneur_2022_887164
crossref_primary_10_3389_fimmu_2021_705772
crossref_primary_10_54101_ACEN_2023_2_7
crossref_primary_10_7759_cureus_23405
crossref_primary_10_1016_j_pmr_2023_04_002
crossref_primary_10_7759_cureus_19036
crossref_primary_10_3390_ijms25084556
crossref_primary_10_1097_WNO_0000000000001362
crossref_primary_10_3390_cells9112360
crossref_primary_10_1097_WNO_0000000000001364
crossref_primary_10_3390_jcdd10040153
crossref_primary_10_1016_j_celrep_2023_113275
crossref_primary_10_3390_healthcare11202800
crossref_primary_10_1016_j_ejpn_2021_06_002
crossref_primary_10_1111_cen3_12676
crossref_primary_10_1016_j_msard_2022_103712
crossref_primary_10_3390_molecules27134142
crossref_primary_10_1007_s10140_020_01840_y
crossref_primary_10_1111_jon_12880
crossref_primary_10_3389_fimmu_2021_645013
crossref_primary_10_3390_v13102091
crossref_primary_10_1016_j_msard_2021_102915
crossref_primary_10_1016_j_msard_2022_103708
crossref_primary_10_7759_cureus_79718
crossref_primary_10_3390_v15071569
crossref_primary_10_3390_jpm14080780
crossref_primary_10_3389_fneur_2022_904796
crossref_primary_10_3390_medicina58020305
crossref_primary_10_1016_j_nerep_2022_100063
crossref_primary_10_1097_WNO_0000000000001812
crossref_primary_10_25259_SNI_192_2022
crossref_primary_10_3233_ADR_230172
crossref_primary_10_1007_s12035_020_02094_y
crossref_primary_10_1007_s13365_021_00959_z
crossref_primary_10_3389_fimmu_2021_755333
crossref_primary_10_1007_s10787_022_01011_0
crossref_primary_10_1016_j_cyto_2022_155873
crossref_primary_10_1016_j_neurol_2022_11_004
crossref_primary_10_1186_s12883_022_02590_9
crossref_primary_10_4103_ijo_IJO_1723_22
crossref_primary_10_1002_cbin_11997
crossref_primary_10_3389_fimmu_2023_1296518
crossref_primary_10_1016_j_jtauto_2025_100280
crossref_primary_10_1007_s00415_021_10780_7
crossref_primary_10_1016_j_nrleng_2022_09_002
crossref_primary_10_1053_j_sult_2024_03_003
crossref_primary_10_1515_revneuro_2020_0070
crossref_primary_10_1007_s12026_023_09371_7
crossref_primary_10_3389_fcell_2020_605972
crossref_primary_10_3389_fneur_2021_660087
crossref_primary_10_1186_s40001_023_01293_2
crossref_primary_10_3390_biomedicines10040774
crossref_primary_10_12688_f1000research_155163_1
crossref_primary_10_2174_1573405620666230328110847
crossref_primary_10_1007_s12035_020_02236_2
crossref_primary_10_1007_s00415_023_11912_x
crossref_primary_10_1007_s12035_021_02464_0
crossref_primary_10_2174_0929867328666210506161543
Cites_doi 10.1016/j.neuro.2016.03.020
10.1016/j.nrl.2020.03.001
10.3109/13550289609146902
10.1016/j.virusres.2014.09.011
10.1212/NXI.0000000000000741
10.1177/1352458518823940
10.1016/S1474-4422(20)30109-5
10.1007/BF00867354
10.1016/j.jneuroim.2017.01.003
10.1128/JVI.00920-08
10.1016/j.ddmod.2020.02.003
10.1212/WNL.0000000000009937
10.1016/j.ijid.2020.03.062
10.1002/ana.410310511
ContentType Journal Article
Copyright 2020 Elsevier B.V.
Elsevier B.V.
Copyright © 2020 Elsevier B.V. All rights reserved.
2020 Elsevier B.V. All rights reserved. 2020 Elsevier B.V.
Copyright_xml – notice: 2020 Elsevier B.V.
– notice: Elsevier B.V.
– notice: Copyright © 2020 Elsevier B.V. All rights reserved.
– notice: 2020 Elsevier B.V. All rights reserved. 2020 Elsevier B.V.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.1016/j.msard.2020.102377
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList

MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2211-0356
EndPage 102377
ExternalDocumentID PMC7340057
32698095
10_1016_j_msard_2020_102377
S2211034820304521
1_s2_0_S2211034820304521
Genre Journal Article
Case Reports
GroupedDBID ---
--K
--M
.1-
.FO
.~1
0R~
1P~
1~.
1~5
4.4
457
4G.
53G
5VS
7-5
8P~
AAEDT
AAEDW
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AATTM
AAXKI
AAXLA
AAXUO
AAYWO
ABBQC
ABCQJ
ABGSF
ABJNI
ABMAC
ABMZM
ABTEW
ABUDA
ABWVN
ABXDB
ACDAQ
ACGFS
ACIEU
ACLOT
ACRLP
ACRPL
ACVFH
ADBBV
ADCNI
ADEZE
ADMUD
ADNMO
ADUVX
AEBSH
AEHWI
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AFJKZ
AFPUW
AFRHN
AFTJW
AFXIZ
AGHFR
AGUBO
AGWIK
AGYEJ
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
APXCP
AXJTR
BKOJK
BLXMC
BNPGV
EBS
EFJIC
EFKBS
EFLBG
EJD
FDB
FEDTE
FIRID
FNPLU
FYGXN
GBLVA
HVGLF
HZ~
KOM
M41
MO0
MOBAO
O-L
O9-
OAUVE
OP~
P-8
P-9
PC.
Q38
ROL
SDF
SEL
SPCBC
SSH
SSN
SSU
SSZ
T5K
Z5R
~G-
~HD
AACTN
AFKWA
AJOXV
AMFUW
RIG
AADPK
AAIAV
ABLVK
ABYKQ
AJBFU
DOVZS
LCYCR
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ID FETCH-LOGICAL-c5477-9001430a508172c97f38d16099755eb7575e47fc4c27e2c325fc97d54b6dbbd43
ISSN 2211-0348
2211-0356
IngestDate Tue Sep 30 16:53:30 EDT 2025
Thu Oct 02 10:51:05 EDT 2025
Thu Apr 03 07:00:59 EDT 2025
Tue Nov 18 21:45:51 EST 2025
Wed Nov 05 20:51:51 EST 2025
Fri Feb 23 02:47:36 EST 2024
Sun Feb 23 10:19:58 EST 2025
Tue Oct 14 19:31:09 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Keywords COVID-19
Demyelinating disease
SARS-CoV-2
MHV-59
Optic neuritis
Language English
License Copyright © 2020 Elsevier B.V. All rights reserved.
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c5477-9001430a508172c97f38d16099755eb7575e47fc4c27e2c325fc97d54b6dbbd43
Notes ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ORCID 0000-0003-0936-5615
0000-0003-3625-0987
0000-0002-3229-0060
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC7340057
PMID 32698095
PQID 2426535868
PQPubID 23479
PageCount 1
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_7340057
proquest_miscellaneous_2426535868
pubmed_primary_32698095
crossref_citationtrail_10_1016_j_msard_2020_102377
crossref_primary_10_1016_j_msard_2020_102377
elsevier_sciencedirect_doi_10_1016_j_msard_2020_102377
elsevier_clinicalkeyesjournals_1_s2_0_S2211034820304521
elsevier_clinicalkey_doi_10_1016_j_msard_2020_102377
PublicationCentury 2000
PublicationDate 2020-10-01
PublicationDateYYYYMMDD 2020-10-01
PublicationDate_xml – month: 10
  year: 2020
  text: 2020-10-01
  day: 01
PublicationDecade 2020
PublicationPlace Netherlands
PublicationPlace_xml – name: Netherlands
PublicationTitle Multiple sclerosis and related disorders
PublicationTitleAlternate Mult Scler Relat Disord
PublicationYear 2020
Publisher Elsevier B.V
Publisher_xml – name: Elsevier B.V
References Shindler, Kenyon, Dutt, Hingley, Das (bib0013) 2008; 82
Marrodan, Alessandro, Farez, Correale (bib0010) 2019; 25
Alberti, Beretta, Piatti (bib0003) 2020; 7
Matías-Guiu, Gomez-Pinedo, Montero-Escribano, Gomez-Iglesias, Porta-Etessam, Matias-Guiu (bib0012) 2020; 35
Donati (bib0007) 2020
Savarin, Bergmann (bib0014) 2017; 308
Zhao, Shen, Zhou, Liu, Chen (bib0004) 2020; 19
Andersen, Lygner, Bergström, Andersson, Vablne (bib0008) 1993; 240
McKay, Jahanfar, Duggan, Tkachuk, Tremlett (bib0009) 2017; 61
Houtman, Fleming (bib0015) 1996; 2
(accessed May 10, 2020).
Zanin, Saraceno, Panciani (bib0005) 2020; 162 (7)
COVID-19 Map - Johns Hopkins Coronavirus Resource Center.
Romero-Sánchez, Díaz-Maroto, Fernández-Díaz (bib0002) 2020
Moriguchi, Harii, Goto (bib0006) 2020; 94
Desforges, Le Coupanec, Stodola, Meessen-Pinard, Talbot (bib0016) 2014; 194
Murray, Brown, Brain, Cabirac (bib0011) 1992; 31
Donati (10.1016/j.msard.2020.102377_bib0007) 2020
Houtman (10.1016/j.msard.2020.102377_bib0015) 1996; 2
Zhao (10.1016/j.msard.2020.102377_bib0004) 2020; 19
Matías-Guiu (10.1016/j.msard.2020.102377_bib0012) 2020; 35
Zanin (10.1016/j.msard.2020.102377_bib0005) 2020; 162 (7)
Romero-Sánchez (10.1016/j.msard.2020.102377_bib0002) 2020
Alberti (10.1016/j.msard.2020.102377_bib0003) 2020; 7
Andersen (10.1016/j.msard.2020.102377_bib0008) 1993; 240
Murray (10.1016/j.msard.2020.102377_bib0011) 1992; 31
Moriguchi (10.1016/j.msard.2020.102377_bib0006) 2020; 94
McKay (10.1016/j.msard.2020.102377_bib0009) 2017; 61
10.1016/j.msard.2020.102377_bib0001
Shindler (10.1016/j.msard.2020.102377_bib0013) 2008; 82
Marrodan (10.1016/j.msard.2020.102377_bib0010) 2019; 25
Savarin (10.1016/j.msard.2020.102377_bib0014) 2017; 308
Desforges (10.1016/j.msard.2020.102377_bib0016) 2014; 194
References_xml – volume: 7
  start-page: e741
  year: 2020
  ident: bib0003
  article-title: Guillain-Barré syndrome related to COVID-19 infection
  publication-title: Neurol. - Neuroimmunol. Neuroinflammation
– volume: 240
  start-page: 417
  year: 1993
  end-page: 422
  ident: bib0008
  article-title: Viral infections trigger multiple sclerosis relapses: a prospective seroepidemiological study
  publication-title: J. Neurol.
– reference: COVID-19 Map - Johns Hopkins Coronavirus Resource Center.
– volume: 61
  start-page: 189
  year: 2017
  end-page: 212
  ident: bib0009
  article-title: Factors associated with onset, relapses or progression in multiple sclerosis: a systematic review
  publication-title: Neurotoxicology
– volume: 308
  start-page: 12
  year: 2017
  end-page: 16
  ident: bib0014
  article-title: Viral-induced suppression of self-reactive T cells: lessons from neurotropic coronavirus-induced demyelination
  publication-title: J. Neuroimmunol.
– volume: 19
  start-page: 383
  year: 2020
  end-page: 384
  ident: bib0004
  article-title: Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence?
  publication-title: Lancet Neurol.
– year: 2020
  ident: bib0002
  article-title: Neurologic manifestations in hospitalized patients with COVID-19: the ALBACOVID registry
  publication-title: Neurology
– volume: 25
  start-page: 891
  year: 2019
  end-page: 901
  ident: bib0010
  article-title: The role of infections in multiple sclerosis
  publication-title: Mult. Scler. J.
– volume: 194
  start-page: 145
  year: 2014
  end-page: 158
  ident: bib0016
  article-title: Human coronaviruses: viral and cellular factors involved in neuroinvasiveness and neuropathogenesis
  publication-title: Virus Res.
– volume: 35
  start-page: 170
  year: 2020
  end-page: 175
  ident: bib0012
  article-title: Should we expect neurological symptoms in the SARS-CoV-2 epidemic?
  publication-title: Neurologia
– reference: (accessed May 10, 2020).
– volume: 162 (7)
  start-page: 1
  year: 2020
  end-page: 4
  ident: bib0005
  article-title: SARS-CoV-2 can induce brain and spine demyelinating lesions
  publication-title: Acta Neurochir. (Wien)
– volume: 94
  start-page: 55
  year: 2020
  end-page: 58
  ident: bib0006
  article-title: A first case of meningitis/encephalitis associated with SARS-Coronavirus-2
  publication-title: Int. J. Infect. Dis.
– volume: 31
  start-page: 525
  year: 1992
  end-page: 533
  ident: bib0011
  article-title: Detection of coronavirus RNA and antigen in multiple sclerosis brain
  publication-title: Ann. Neurol.
– year: 2020
  ident: bib0007
  article-title: Viral infections and multiple sclerosis
  publication-title: Drug Discov. Today Dis. Models
– volume: 82
  start-page: 8882
  year: 2008
  end-page: 8886
  ident: bib0013
  article-title: Experimental optic neuritis induced by a demyelinating strain of mouse hepatitis virus
  publication-title: J. Virol.
– volume: 2
  start-page: 361
  year: 1996
  end-page: 376
  ident: bib0015
  article-title: Pathogenesis of mouse hepatitis virus-induced demyelination
  publication-title: J. Neurovirol.
– volume: 162 (7)
  start-page: 1
  year: 2020
  ident: 10.1016/j.msard.2020.102377_bib0005
  article-title: SARS-CoV-2 can induce brain and spine demyelinating lesions
  publication-title: Acta Neurochir. (Wien)
– volume: 61
  start-page: 189
  year: 2017
  ident: 10.1016/j.msard.2020.102377_bib0009
  article-title: Factors associated with onset, relapses or progression in multiple sclerosis: a systematic review
  publication-title: Neurotoxicology
  doi: 10.1016/j.neuro.2016.03.020
– volume: 35
  start-page: 170
  year: 2020
  ident: 10.1016/j.msard.2020.102377_bib0012
  article-title: Should we expect neurological symptoms in the SARS-CoV-2 epidemic?
  publication-title: Neurologia
  doi: 10.1016/j.nrl.2020.03.001
– volume: 2
  start-page: 361
  year: 1996
  ident: 10.1016/j.msard.2020.102377_bib0015
  article-title: Pathogenesis of mouse hepatitis virus-induced demyelination
  publication-title: J. Neurovirol.
  doi: 10.3109/13550289609146902
– volume: 194
  start-page: 145
  year: 2014
  ident: 10.1016/j.msard.2020.102377_bib0016
  article-title: Human coronaviruses: viral and cellular factors involved in neuroinvasiveness and neuropathogenesis
  publication-title: Virus Res.
  doi: 10.1016/j.virusres.2014.09.011
– volume: 7
  start-page: e741
  year: 2020
  ident: 10.1016/j.msard.2020.102377_bib0003
  article-title: Guillain-Barré syndrome related to COVID-19 infection
  publication-title: Neurol. - Neuroimmunol. Neuroinflammation
  doi: 10.1212/NXI.0000000000000741
– volume: 25
  start-page: 891
  year: 2019
  ident: 10.1016/j.msard.2020.102377_bib0010
  article-title: The role of infections in multiple sclerosis
  publication-title: Mult. Scler. J.
  doi: 10.1177/1352458518823940
– volume: 19
  start-page: 383
  year: 2020
  ident: 10.1016/j.msard.2020.102377_bib0004
  article-title: Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence?
  publication-title: Lancet Neurol.
  doi: 10.1016/S1474-4422(20)30109-5
– volume: 240
  start-page: 417
  year: 1993
  ident: 10.1016/j.msard.2020.102377_bib0008
  article-title: Viral infections trigger multiple sclerosis relapses: a prospective seroepidemiological study
  publication-title: J. Neurol.
  doi: 10.1007/BF00867354
– volume: 308
  start-page: 12
  year: 2017
  ident: 10.1016/j.msard.2020.102377_bib0014
  article-title: Viral-induced suppression of self-reactive T cells: lessons from neurotropic coronavirus-induced demyelination
  publication-title: J. Neuroimmunol.
  doi: 10.1016/j.jneuroim.2017.01.003
– volume: 82
  start-page: 8882
  year: 2008
  ident: 10.1016/j.msard.2020.102377_bib0013
  article-title: Experimental optic neuritis induced by a demyelinating strain of mouse hepatitis virus
  publication-title: J. Virol.
  doi: 10.1128/JVI.00920-08
– year: 2020
  ident: 10.1016/j.msard.2020.102377_bib0007
  article-title: Viral infections and multiple sclerosis
  publication-title: Drug Discov. Today Dis. Models
  doi: 10.1016/j.ddmod.2020.02.003
– ident: 10.1016/j.msard.2020.102377_bib0001
– year: 2020
  ident: 10.1016/j.msard.2020.102377_bib0002
  article-title: Neurologic manifestations in hospitalized patients with COVID-19: the ALBACOVID registry
  publication-title: Neurology
  doi: 10.1212/WNL.0000000000009937
– volume: 94
  start-page: 55
  year: 2020
  ident: 10.1016/j.msard.2020.102377_bib0006
  article-title: A first case of meningitis/encephalitis associated with SARS-Coronavirus-2
  publication-title: Int. J. Infect. Dis.
  doi: 10.1016/j.ijid.2020.03.062
– volume: 31
  start-page: 525
  year: 1992
  ident: 10.1016/j.msard.2020.102377_bib0011
  article-title: Detection of coronavirus RNA and antigen in multiple sclerosis brain
  publication-title: Ann. Neurol.
  doi: 10.1002/ana.410310511
SSID ssj0000651461
Score 2.5308552
Snippet •The first case of multiple sclerosis (MS) shortly after COVID-19 is presented.•Viral infections strongly relate to MS onset and its relapses.•SARS-CoV-2 can...
Highlights•The first case of multiple sclerosis (MS) shortly after COVID-19 is presented. •Viral infections strongly relate to MS onset and its relapses....
SARS-CoV-2 infection can produce neurological features. The most common are headache, anosmia and dysgeusia but patients may also develop other central nervous...
• The first case of multiple sclerosis (MS) shortly after COVID-19 is presented. • Viral infections strongly relate to MS onset and its relapses. • SARS-CoV-2...
SourceID pubmedcentral
proquest
pubmed
crossref
elsevier
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 102377
SubjectTerms Adult
Betacoronavirus
Coronavirus Infections - complications
COVID-19
Demyelinating disease
Female
Humans
MHV-59
Multiple Sclerosis - epidemiology
Multiple Sclerosis - pathology
Neurology
Optic neuritis
Original
Pandemics
Pneumonia, Viral - complications
SARS-CoV-2
Title Multiple sclerosis following SARS-CoV-2 infection
URI https://www.clinicalkey.com/#!/content/1-s2.0-S2211034820304521
https://www.clinicalkey.es/playcontent/1-s2.0-S2211034820304521
https://dx.doi.org/10.1016/j.msard.2020.102377
https://www.ncbi.nlm.nih.gov/pubmed/32698095
https://www.proquest.com/docview/2426535868
https://pubmed.ncbi.nlm.nih.gov/PMC7340057
Volume 45
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVESC
  databaseName: ScienceDirect Freedom Collection
  customDbUrl:
  eissn: 2211-0356
  dateEnd: 20210531
  omitProxy: false
  ssIdentifier: ssj0000651461
  issn: 2211-0348
  databaseCode: AIEXJ
  dateStart: 20120101
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3fb9MwELbYhqa9IH7TAVOQeMRV4thx_FhtY4C0aaID9c1KHFd0atOq2djEX8_Zsd123QY88BJFic9pfWf78_n8HULvYU6nJa8EzgBcY6oVxyKrCFYiL_NYxbEmhU02wU9O8sFAnDpXdmPTCfC6zq-vxey_qhqegbLN0dl_UHeoFB7APSgdrqB2uP6V4o99iGADL2AOHBnGhfF4emW5t3tf-3h_-h2TEIZVL-PTW4RtALoJmQNoWjmuzgDET4txMV1xqhrHtN19T4x3Gh_Y-4Pi18qph6N5ATaBj5wDerHrM4GP4r6TB3uyYr5255yAlagPc4O5xQ5ihBgXbNqSh_sRl7KlIdNwR7SZXNZG89axcN6dNNBbuqb-7nppaP3ZxOoSkKjI4zZn5w0Sbf9qA20RzgQMf1u9z4eDL8EdB0jMZDj3vFQ2AnDtszto21d0F4xZX6bcjLZdgi9nj9Ejt-6Ieq29PEEPdP0UbR-7yIpnKPGaj4Lmo2A20cJsomA2z9G3j4dn-5-wS6eBFaNmo94sh9O4AEgOqFUJPkzzKsnM0WnGdMkBuGvKh4oqwjVRKWFDKFQxWmZVWVY0fYE262mtX6GI84QZKsUioSCSsUIlqhBDTSkrE1GIDiK-daRyXPMm5clY-qDCc2lbV5rWlW3rdtCHIDRrqVbuL059s0t_ihjmPQnGc78Yv01MN64LNzKRDZGx7BvTjQ33k40mIEkHZUHSwdMWdv75k--8VUgYvM2OXFHr6WUjDT5mKcuzvINetlYS_rq3NPjBK_YTChhi-NU39eiHJYjnKTWHzHfvrPM12ln01jdo82J-qd-ih-rnxaiZ76ENPsj3XA_5Da7DzAU
linkProvider Elsevier
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Multiple+sclerosis+following+SARS-CoV-2+infection&rft.jtitle=Multiple+sclerosis+and+related+disorders&rft.au=Palao%2C+M&rft.au=Fern%C3%A1ndez-D%C3%ADaz%2C+E&rft.au=Gracia-Gil%2C+J&rft.au=Romero-S%C3%A1nchez%2C+C+M&rft.date=2020-10-01&rft.eissn=2211-0356&rft.volume=45&rft.spage=102377&rft_id=info:doi/10.1016%2Fj.msard.2020.102377&rft_id=info%3Apmid%2F32698095&rft.externalDocID=32698095
thumbnail_m http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F22110348%2FS2211034820X00071%2Fcov150h.gif